, , the live, attenuated Listeria monocytogenes immunotherapy business, has received formal authorization from the Medicines Controller General India to conduct a Stage II medical trial of ADXS11-001, the Company’s flagship drug construct, among 110 females with advanced, metastatic cervical tumor that has progressed after treatment with cytotoxic therapy SildenafilOnline.biz . 55 females will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy. Historically, even when given the most effective regimen tested to date, these patients experienced a median survival of around six a few months with just five % surviving one calendar year.

If a drug shows similar or superior efficacy versus another, and costs less, chances are to be preferred. Sadly, these analyses disregard the real-world reporting of ADRs once a drug is used among broad patient populations. Typically, these real-world reports, which are essential in discovering new medication risks that had not been identified in pre-market medication testing, uncover three-times more ADRs than clinical trials.g., injury, medical center entrance/readmission, disability and/or death). The ability to obtain, quickly review and proactively act about these RxCost data will improve patient outcomes and lower system-wide costs dramatically.S. Health care system $25 billion in 2013.